Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8581591 | 0.86 | CA2 (0.51) | GAAMAP3K5KDM4EHTTNPSR1 | |
| SCHEMBL7801323 | 0.85 | KDM4E (0.54) | MAP3K5KDM4ENPSR1KMT2AHSD17B10 | |
| SCHEMBL8580625 | 0.85 | SLC9A1 (0.45) | KDM4EHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL14871092 | 0.84 | GAA (0.44) | GAAKDM4EHTTNPSR1MEN1 | |
| SCHEMBL8574362 | 0.83 | GAA (0.56) | GAAKDM4EHTTNPSR1MEN1 | |
| SCHEMBL8582018 | 0.81 | SLC9A1 (0.45) | GAAKDM4EHTTNPSR1MEN1 | |
| SCHEMBL8581653 | 0.81 | HTT (0.45) | GAAKDM4EHTTNPSR1MEN1 | |
| SCHEMBL8573449 | 0.81 | CA2 (0.41) | KDM4ENPSR1KMT2AHSD17B10SMN1; SMN2 | |
| SCHEMBL8581950 | 0.81 | ALDH1A1 (0.40) | KDM4EHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL8573417 | 0.80 | GAA (0.43) | GAAKDM4EHTTNPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054028-A1 | PD-L1 ANTAGONIST COMPOUND | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2023-02-23 | — | — | US | disclosed |
| EP-4083032-A1 | PD-L1 ANTAGONIST COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021129584-A1 | PD-L1 ANTAGONIST COMPOUND | 杭州阿诺生物医药科技有限公司 | 2021-07-01 | — | — | WO | disclosed |
| US-5840761-A | Alkylbenzoylguanidine derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054028-A1 | PD-L1 ANTAGONIST COMPOUND | CD274, PDCD1LG2, PDCD1 | GAA 1336/4885MAP3K5 503/4885KDM4E 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.